A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer

Parnis, Francis; Coleman, Robert E.; Harper, Peter; Pickering, Diane L.; Topham, C.; Whittington, J. R.; Tedeschi, Michèle

doi:10.1016/0959-8049(95)00310-f

Cited by 17 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the four double-blind, placebo-controlled RCTs, two studied ovarian cancer patients (22, 23). In a trial of 151 ovarian cancer patients, Smyth et al .…”

Section: Resultsmentioning

confidence: 99%

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Nakayama¹,

Alladin

Igbokwe

et al. 2011

Cancer Investigation

View full text Add to dashboard Cite

The risk–benefit ratio for concurrent use of dietary antioxidants with chemotherapy or radiation therapy is a controversial topic. In this review, the medical literature on concurrent antioxidant use with chemotherapy or radiotherapy was assessed and further steps for generating evidence-based guidelines are suggested. The clinical cancer research community should cooperate and focus new studies on the use of a specific combination of antioxidant and chemotherapy or radiotherapy, and determine optimal doses for a specific cancer setting. Mechanistic studies on the interaction between antioxidants and conventional cancer therapy could lead to novel biomarkers for assessing dose adequacy.

show abstract

“…Among the four double-blind, placebo-controlled RCTs, two studied ovarian cancer patients (22, 23). In a trial of 151 ovarian cancer patients, Smyth et al .…”

Section: Resultsmentioning

confidence: 99%

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Nakayama¹,

Alladin

Igbokwe

et al. 2011

Cancer Investigation

View full text Add to dashboard Cite

show abstract

“…Four trials to date have been conducted (three in ovarian cancer, one in gastric cancer) using various doses of glutathione with cisplatin chemotherapy. Parnis et al showed no difference in neuropathy between groups, and the trial was aborted because of unacceptable ototoxicity [36]. Bogliun et al found no difference in neuropathy between groups at week 9 of therapy, but a trend to less neuropathy with glutathione with more prolonged treatment [12].…”

Section: Glutathionementioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies

Ocean

Vahdat

2004

Support Care Cancer

105

129

View full text Add to dashboard Cite

Peripheral neuropathy is a major dose-limiting side effect of many chemotherapeutic agents. The type and degree of neuropathy depend on the chemotherapy drug, dose-intensity, and cumulative dose. Disabling peripheral neuropathy has a significant negative impact on quality of life. Accordingly, a reliable assessment of chemotherapy-induced peripheral neurotoxicity is necessary, especially if potential neuroprotective agents are to be investigated. Chemoprotectants are agents that have been developed to ameliorate the toxicity associated with cytotoxic drugs. They aim to provide site-specific protection for normal tissues, without compromising antitumor efficacy. Several chemoprotectant compounds have been studied in recent clinical trials. These trials must include sufficient dose-limiting events for study and assessment of both toxicity and antitumor effect. A future avenue of investigation includes the identification of patients at higher risk for the development of peripheral neuropathy based on their genotype. Identification of these higher-risk patients may enable us to devise prevention strategies prior to the onset of this potentially debilitating complication.

show abstract

“…In humans, the antioxidants acetylcysteine (Riga et al 2013 ;Yoo et al 2013 ), amifostine (Fouladi et al 2008 ;Katzenstein et al 2009 ;Gallegos-Castorena et al 2007 ;Ekborn et al 2004 ;Sastry and Kellie 2005 ;Marina et al 2005 ;Fisher et al 2004 ;Planting et al 1999 ;Kemp et al 1996 ), diethyldithiocarbamate (Berry et al 1990 ;Gandara et al 1995 ), GSH (Parnis et al 1995 ), and sodium thiosulfate (Zuur et al 2007 ;Rasch et al 2010 ;van Rijswijk et al 1997 ) have been investigated as potential candidates to reduce the ototoxic effects of cisplatin. Some support for otoprotection has been obtained with acetylcysteine (Riga et al 2013 ), amifostine (Fouladi et al 2008 ), and thiosulfate (Zuur et al 2007 ;Rasch et al 2010 ;van Rijswijk et al 1997 ).…”

Section: Antioxidants Used In Humansmentioning

confidence: 99%

Hearing Loss After Cisplatin: Oxidative Stress Pathways and Potential for Protection

Laurell

Pierre

2015

Free Radicals in ENT Pathology

View full text Add to dashboard Cite

show abstract

A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer

Cited by 17 publications

References 3 publications

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies

Hearing Loss After Cisplatin: Oxidative Stress Pathways and Potential for Protection

Contact Info

Product

Resources

About